The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
Abstract
PURPOSE: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non–Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m 2 infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m 2 over 1 hour) or 75 mg/m 2 of cisplatin alone, every 3 weeks for a maximum of eight cycles. RESULTS: A total of 446 patients with NSCLC (17% with stage IIIB disease and pleural effusions; 83% with stage IV disease) were entered onto the study. Karnofsky performance status (KPS) was ≥ 60 for all patients (for 10%, KPS = 60; for 90%, KPS = 70 to 100). Sixty patients (14%) had clinically stable brain metastases. The median survival was significantly longer (34.6 v 27.7 weeks; P = .0078) and the response rate was significantly greater (27.5% v 13.7%; P < .001) for patients who received tirapazamine plus cisplatin (n = 218) than for those who received cisplatin alone (n = 219). The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting. There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine. CONCLUSION: The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2459 · Cited by 555
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Brown, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.220 · Cited by 366
Klastersky, J., Sculier, J. P., Lacroix, H., Dabouis, G., Bureau, G., Libert, P., Richez, M., Ravez, P., Vandermoten, G., & Thiriaux, J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1556 · Cited by 246
Gatzemeier, U., von Pawel, J., Gottfried, M., Velde, G. P. M. T., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3390 · Cited by 226
Self-citationTumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie, M. J., & Brown, J. M. (1993) · PubMed · Cited by 143
Grau, C., & Overgaard, J. (1988) · Radiotherapy and Oncology · doi:10.1016/0167-8140(88)90225-3 · Cited by 91
Cited by
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia
Carreau, A., Hafny‐Rahbi, B. E., Matejuk, A., Grillon, C., & Kieda, C. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01258.x · Cited by 1,246
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Multidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., & Peters, L. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2878 · Cited by 541
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L., & Kolb, H. C. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 420
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes
Harrison, L. B., Chadha, M., Hill, R. J., Hu, K., & Shasha, D. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-492 · Cited by 376
Tumor Hypoxia in Cancer Therapy
Brown, J. M. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35015-5 · Cited by 359
Delbaldo, C., Michiels, S., Syz, N., Soria, J.-C., Le Chevalier, T., & Pignon, J.-P. (2004) · JAMA · doi:10.1001/jama.292.4.470 · Cited by 337
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Ramalingam, S., & Belani, C. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333
Prodrug strategies in cancer therapy
Denny, W. A. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01253-3 · Cited by 290
Bussink, J., Kaanders, J. H. A. M., & van der Kogel, A. J. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(03)00011-2 · Cited by 276
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Targeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Mechanisms of Disease: Cancer stem cells--targeting the evil twin
Trumpp, A., & Wiestler, O. D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1110 · Cited by 199
Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
DiSilvestro, P. A., Ali, S., Craighead, P. S., Lucci, J. A., Lee, Y.-C., Cohn, D. E., Spirtos, N. M., Tewari, K. S., Muller, C., Gajewski, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4265 · Cited by 127
Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1107 · Cited by 82
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Metadata
- Authors
- von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., & Treat, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-03-13
- Volume
- 18
- Issue
- 6
- Pages
- 1351-1359
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2271870719
- Cited by
- 285
- References
- 15
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.